Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

November 30, 2011

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Dasatinib (Sprycel)

100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.

Trial Locations (7)

4031

University Hospital, Basel

Unknown

E Herriot Hospital, Lyon

University Hospital, Hamburg

Uniklinik Leipzig, Leipzig

Stiftung Deutsche Klinik für Diagnostik, Wiesbaden

Hopitaux Universitaires de Geneve, Geneva

W12 0NN

Hammersmith Hospital, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

European Society for Blood and Marrow Transplantation

NETWORK